Cutaneous Mastocytosis
Conditions
Keywords
Cutaneous Mastocytosis, Topical treatment
Brief summary
The current study will investigate the effects of TF002 on cutaneous mastocytosis or cutaneous involvement of systemic mastocytosis as compared to clobetasol proprionate (positive control) and a general skin care product without active ingredient targeting mastocytosis (negative control) based on clinical effects on Darier´s signs and the histological evaluation of mast cell numbers in skin bioptic material.
Detailed description
This is a randomised, double-blind, placebo- and active-controlled study with intra-individual comparison of test areas. The primary study target is to evaluate the safety and efficacy of TF002 for the treatment of cutaneous mastocytosis or systemic mastocytosis with skin involvment. The treatment period of 14 days was adjusted to the maximum recommended treatment period for the comparator Dermoxinale®. Since there are no approved therapies for this indication a placebo controlled design was chosen. There are some reports about transient treatment effects using high potent steroids like clobetasol in mastocytosis. This triggered the decision to use Dermoxinale® as positive control. To validate the clinical scores used in the study, surrogate markers describing the Darier´s sign (thermography, volumetric test) will be evaluated optionally.
Interventions
DRUGTF 002
Sponsors
JADO Technologies GmbH
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Chronic stable symptomatic maculopapulous cutaneous mastocytosis or systemic mastocytosis with involvement of the skin and with positive Darier's Sign * 3 comparable skin lesional areas * Otherwise healthy according to physical examination * Informed consent signed and dated
Exclusion criteria
* Aggressive systemic mastocytosis * Other dermatological diseases at treated skin site * Known hypersensitivity to study drugs or their components * Mental disorders * Drug or alcohol dependency * Any other chronic or acute illness requiring systemic treatment which might have any influence on the outcome of the study in the 4 weeks before start of treatment and during the study (investigator's decision). * Immunodeficiency including HIV * Pregnancy or lactation * Participation in another clinical trial within the last 30 days * Malignant skin lesions * Radiation therapy of target areas excluding UV therapy longer then 4 weeks before start of study treatment * Dermal comorbidities within the target areas * Any concomitant medication which might influence the study objectives or are known to provoke or aggravate mastocytosis
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical evaluation of treatment response | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of skin mast cells | — |
| Volumetric and thermographic analyses | — |
Countries
Germany
Outcome results
None listed